New vaccine provides full protection against malaria
The vaccine showed that the two-component vaccine regimen provided mice with 100 percent protection against malaria when they were infected with a rodent malaria parasite. The success is attributed to the vaccine provoking an immune response that isolates the circumsporozoite protein antigen in Plasmodium falciparum, which is the parasite that causes the majority of malaria deaths.
“The Plasmodium falciparum parasite is able to adapt to the human host and evade its immune response very effectively and to date, the most effective subunit, recombinant vaccine prevents infection by malaria parasites in only 30 to 50 percent of those immunized,” B. Kim Lee Sim, president and chief scientific officer of Protein Potential, said. “In order to be broadly adopted by travelers and the military, a vaccine must provide more than 80 percent protection against infection for at least six months. There is a significant need for more effective vaccines for malaria and we believe the data shared today represent a very positive first step. We look forward to IND-enabling studies and clinical testing in humans.”
The data was presented Wednesday in Philadelphia at the 64th Annual Meeting of the American Society for Tropical Medicine and Hygiene Meeting under Post Session C, or Abstract No. 1647.